May the can­dle burn for­ev­er: Po­lite re­minders about the JP­Mor­gan con­fab

Ed­i­tor’s Note: Biotech Voic­es is a con­tributed col­umn from se­lect End­points News read­ers. Be­low is an anony­mous com­men­tary from a pub­lic biotech CEO who was in­spired to write a de­fense of JP­Mor­gan fol­low­ing a litany of com­plaints.


Every year we start the biotech cal­en­dar with a busy Jan­u­ary pil­grim­age where JP­Mor­gan hosts a wide­ly at­tend­ed get to­geth­er that at­tracts big and small to the San Fran­cis­co Union Square neigh­bor­hood. De­spite the peren­ni­al suc­cess of this event, it is in­ter­est­ing to hear re­cent com­plaints from mul­ti­ple voic­es, sug­gest­ing di­min­ish­ing re­turns and wan­ing en­thu­si­asm for fu­ture par­tic­i­pa­tion. While all of these com­plaints may be valid, let’s not go over­board and for­get why this event is a key land­mark.

On be­half of the many ben­e­fi­cia­ries of the JP­Mor­gan con­fab, I would like to pro­vide re­spect­ful and po­lite re­minders re­gard­ing the un­par­al­leled val­ue of this meet­ing. I have been com­ing to JP­Mor­gan for ap­prox­i­mate­ly 20 years, no spe­cif­ic fi­nan­cial con­nec­tion with JP­Mor­gan it­self, but I like many oth­ers hope and pray that our in­dus­try’s can­dle burns bright­ly, and that the Jan­u­ary mo­men­tum cre­at­ed by JP­Mor­gan’s con­fab is peren­ni­al.

Re­minder #1: The core pur­pose is pub­lic bio­phar­ma com­pa­ny guid­ance. The heart of this event, lo­cat­ed on the mez­za­nine floor of the West­in St. Fran­cis, is the need for each pub­lic com­pa­ny to es­tab­lish guid­ance for what they seek to achieve dur­ing the cal­en­dar year. An as­ton­ish­ing­ly high num­ber of well-qual­i­fied pub­lic mar­ket in­vestors come to pre­sen­ta­tions, have 1-on-1 sched­uled meet­ings with com­pa­nies and ex­change ideas in­side the hall­ways of the West­in through­out the week. The qual­i­ty and quan­ti­ty of in­flu­en­tial in­vestors at JP­Mor­gan al­lows large phar­ma, and fledg­ling pub­lic biotechs, to reach a wide au­di­ence in per­son on a sin­gle trip. This is why the event ex­ists and is high­ly re­spect­ed.

Re­minder #2: Gets the buzz go­ing. An enor­mous, per­haps un­re­al­ized, ben­e­fit of JP­Mor­gan is how it tends to ig­nite in­dus­try mo­men­tum each year. We should all re­mem­ber that we are in a high­ly risky busi­ness with more fre­quent fail­ures than suc­cess­es, and it would be easy for us to be­come dour on the chal­lenges of drug de­vel­op­ment. The in­ten­tion­al hold-back of good news by many com­pa­nies un­til JP­Mor­gan cre­ates a spring-load ef­fect that like­ly dri­ves in­vest­ment and risk cap­i­tal cy­cles through the rest of the year. The event ma­te­ri­al­izes themes re­gard­ing how phar­ma is like­ly to be­have, how the mar­kets are like­ly to play and what tech­nol­o­gy waves are go­ing to be an­tic­i­pat­ed for the rest of the year. With­out this, we would like­ly grap­ple for pos­i­tive news, or even di­rec­tion, for months in the new year.

Re­minder #3: The by­stander ef­fect. Many, many biotech com­pa­nies have been launched, fi­nanced, bought and part­nered dur­ing this week with­out hold­ing an ac­tu­al in­vite to JP­Mor­gan it­self. A by­stander ef­fect is cre­at­ed be­cause every ma­jor phar­ma hosts meet­ings out­side of the core meet­ing, pro­vid­ing a tar­get rich en­vi­ron­ment for emerg­ing com­pa­nies to sell their wares. Even if these meet­ings are short, and mere­ly in­tro­duc­to­ry in na­ture, they pro­vide an av­enue for phar­ma mon­ey to meet biotech as­sets. Al­lows phar­ma to triage who they want to li­cense or buy for their strate­gic ther­a­peu­tic area needs dur­ing the com­ing year. This is worth gold for every emerg­ing biotech com­pa­ny that wants to con­tem­plate a part­ner­ship to fur­ther their busi­ness. While per­haps not as large as some oth­er part­ner­ing-on­ly fo­cused events, the by­stander ef­fect of JP­Mor­gan is a life-line for key parts of the in­dus­try.

Re­minder #4: The de­mand-and-sup­ply pen­du­lum. The cost of at­tend­ing JP­Mor­gan, or be­ing a by­stander, has in­creased re­mark­ably over the years. The in­dus­try is gath­er­ing mo­men­tum, hir­ing more peo­ple, de­ploy­ing more cap­i­tal and there­fore it is no sur­prise that peo­ple are will­ing to spend more to at­tend the bio­phar­ma su­per­bowl. We are at a tip­ping point where peo­ple are dis­gust­ed, but this will not lead to a dra­mat­ic pull back but more of a grad­ual re­cal­i­bra­tion. De­pend­ing on busi­ness mod­els, some com­pa­nies ap­pro­pri­ate­ly will not find the cost to be worth­while and will hence make de­ci­sions ac­cord­ing­ly next year, which will bring the pen­du­lum back to a point where San Fran­cis­co ho­tels and restau­rants will ad­just prices clos­er to nor­mal lev­els. For most of us, the cost is def­i­nite­ly worth­while.

Re­minder #5: Thank you JP­Mor­gan an­a­lysts. If any­one has the right to com­plain, it’s the JP­Mor­gan an­a­lyst team that is re­spon­si­ble for cov­er­ing >200 pre­sent­ing com­pa­nies at this con­fer­ence. It is their work that at­tracts pub­lic com­pa­nies and in­vestors to at­tend. I can­not imag­ine the hours they (Chris, Cory, Anu­pam, Jes­si­ca, Er­ic and oth­ers) must put in to pre­pare for com­pa­ny guid­ance and then write re­ports on each com­pa­ny post-pre­sen­ta­tion. Every pub­lic com­pa­ny CEO ap­pre­ci­ates your ef­fort.

I wrote this anony­mous­ly in or­der to avoid dis­trac­tion from my of­fi­cial com­pa­ny nar­ra­tive, but I rep­re­sent a con­tin­gent of bio­phar­ma CEOs that are thank­ful for what our in­dus­try has be­come and the role that the JP­Mor­gan con­fer­ence has played over the years. May the can­dle burn for­ev­er.


Im­age: West­in St. Fran­cis ho­tel SHEHLA SHAKOOR for END­POINTS NEWS

Brent Saunders [Getty Photos]

UP­DAT­ED: Ab­b­Vie seals $63B deal to buy a trou­bled Al­ler­gan — spelling out $1B in R&D cuts

Brent Saunders has found his way out of the current fix he’s in at Allergan $AGN. He’s selling the company to AbbVie for $63 billion in the latest example of the hot M&A market in biopharma.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,500+ biopharma pros reading Endpoints daily — and it's free.

Richard Gonzalez testifying in front of Senate Finance Committee, February 2019 [AP Images]

Ab­b­Vie's $63B buy­out spot­lights the re­turn of ma­jor M&A deals — de­spite the back­lash

Big time M&A is back. But for how long?

Over the past 18 months we’ve now seen three ma­jor buy­outs an­nounced: Take­da/Shire; Bris­tol-My­ers/Cel­gene and now Ab­b­Vie/Al­ler­gan. And with this lat­est deal it’s in­creas­ing­ly clear that the sharp fall from grace suf­fered by high-pro­file play­ers which have seen their share prices blast­ed has cre­at­ed an open­ing for the growth play­ers in big phar­ma to up their game — in sharp con­trast to the pop­u­lar bolt-on deals that have been dri­ving the growth strat­e­gy at No­var­tis, Mer­ck, Roche and oth­ers.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,500+ biopharma pros reading Endpoints daily — and it's free.

SQZ, Ery­tech kick off $57M cell ther­a­py part­ner­ship; Jean-Paul Kress lands new CEO gig at Mor­phoSys

→ In a mar­riage of two tech­nolo­gies meant to make cell ther­a­pies more pow­er­ful, SQZ Biotech is team­ing up with France’s Ery­tech Phar­ma for a col­lab­o­ra­tion, with $57 mil­lion re­served for the first project and $50 mil­lion for each sub­se­quent ap­proval (prod­uct or in­di­ca­tion). Hav­ing ac­cess to Ery­tech’s method of fash­ion­ing ther­a­peu­tics from red blood cells, the Cam­bridge, MA-based com­pa­ny said, will am­pli­fy SQZ’s cell en­gi­neer­ing ca­pa­bil­i­ties and al­low them to de­vleop a new class of im­munomod­u­la­to­ry ther­a­pies. Its own tech — so far ap­plied in can­cer but al­so has po­ten­tial in di­a­betes — tem­po­rary dis­rupts the cell mem­brane by squeez­ing the cell, thus cre­at­ing a brief win­dow for tar­get ma­te­ri­als such as anti­gens to en­ter.

FDA re­jects Ac­er's rare dis­ease drug, asks for new tri­al — shares crater

Ac­er Ther­a­peu­tics’ bid to re­pur­pose celipro­lol — a be­ta-block­er on the mar­ket for hy­per­ten­sion — as a treat­ment for a rare, in­her­it­ed con­nec­tive tis­sue dis­or­der has hit a se­vere set­back. The New­ton, Mass­a­chu­setts-based com­pa­ny on Tues­day said the FDA re­ject­ed the drug and has asked for an­oth­er clin­i­cal tri­al.

The com­pa­ny’s shares $AC­ER cratered near­ly 77% to $4.47 in Tues­day morn­ing trad­ing.

Tasly Bio­phar­ma pitch­es long-await­ed IPO — will it trig­ger an­oth­er $1B gold rush on HKEX?

In the run up to the Hong Kong stock ex­change’s an­tic­i­pat­ed rule change — open­ing the door for Chi­nese pre-rev­enue biotechs to go pub­lic clos­er to home — more than a year ago, Tasly Bio­phar­ma was one of the big play­ers whose ru­mored in­ter­est helped stoke en­thu­si­asm for the new list­ing venue. The com­pa­ny has since kept the drum­roll rum­bling in the back­ground, rais­ing a pre-IPO round and con­vinc­ing part­ner Trans­gene to swap own­er­ship in a joint ven­ture for eq­ui­ty. Now the oth­er shoe has fi­nal­ly dropped as ex­ecs out­line plans for a pipeline dom­i­nat­ed by car­dio­vas­cu­lar drugs.

UP­DAT­ED: In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

Apart from revealing its checkpoint inhibitor Opdivo blew a big liver cancer study on Monday, Bristol-Myers Squibb said its plans to swallow Celgene will require the sale of blockbuster psoriasis treatment Otezla to keep the Federal Trade Commission (FTC) at bay.

The announcement — which has potentially delayed the completion of the takeover to early 2020 — irked investors, triggering the New York-based drugmaker’s shares to tumble Monday morning in premarket trading.

Celgene’s Otezla, approved in 2014 for psoriasis and psoriatic arthritis, is a rising star. It generated global sales of $1.6 billion last year, up from the nearly $1.3 billion in 2017. Apart from the partial overlap of Bristol-Myers injectable Orencia, the company’s rival oral TYK2 psoriasis drug is in late-stage development, after the firm posted encouraging mid-stage data on the drug, BMS-986165, last fall. With Monday’s decision, it appears Bristol-Myers is favoring its experimental drug, and discounting Otezla’s future.

The move blindsided some analysts. Credit Suisse’s Vamil Divan noted just days ago:

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,500+ biopharma pros reading Endpoints daily — and it's free.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

With 4 more biotech IPOs due to wrap up Q2, how is the class of 2019 far­ing?

With 22 biotech IPOs on the books and four more set to price in the last week of June, in­vest­ment ad­vis­er Re­nais­sance Cap­i­tal has tak­en the pulse of the re­cent rush.

By the IPO ex­perts’ count, 25 out of 32 health­care of­fer­ings this year have been from biotechs — dif­fer­ing slight­ly from Brad Lon­car’s tal­ly — and the over­all pic­ture is one of un­der­per­for­mance. While they av­er­aged a first-day re­turn of 9.0%, col­lec­tive­ly they have trad­ed down to a 5.9% re­turn. Turn­ing Point $TP­TX and Cor­texyme $CRTX emerged on top at the half-year mark, ris­ing 135% and 109% re­spec­tive­ly.

Eye­ing a $500M peak sales pot, Almi­rall dou­bles down on le­brik­izum­ab as Der­mi­ra lines up PhI­II

With eyes on what it be­lieves is a $500 mil­lion peak rev­enue op­por­tu­ni­ty in Eu­rope, Barcelona-based Almi­rall has stepped up with $50 mil­lion in cash to take up the op­tion on Der­mi­ra’s IL-13 an­ti-in­flam­ma­to­ry drug le­brik­izum­ab just ahead of the start of Phase III. And there’s an­oth­er $30 mil­lion due as the late-stage pro­gram gets geared up.

That shouldn’t be long from now, as Der­mi­ra ex­pects to be­gin the late-stage tri­al work for atopic der­mati­tis be­fore the end of this year as it fol­lows a trail that ex­ecs in­sist leads to block­buster re­turns. Along the way, they’ll need to take on the 600-pound go­ril­la in atopic der­mati­tis: the IL-13/IL-4 drug Dupix­ent, from Re­gen­eron and Sanofi. Ri­vals al­so in­clude Leo Phar­ma, in its piv­otal with tralok­izum­ab, and Anap­tys­Bio in the hunt with a mid-stage pro­gram for etokimab, pre­vi­ous­ly re­ferred to as ANB020.